Hulk Hogan, wrestling icon, dies at 71 in Florida home
CAMBRIDGE, UK - EDX Medical (TASE:BLWV) Group plc (AQSE:EDX), a company specializing in the development of digital diagnostic tools for personalized healthcare, disclosed that its CEO, Dr. Michael Hudson (NYSE:HUD), has transferred a portion of his shares into an ISA account. On Monday, Dr. Hudson moved 170,226 ordinary shares from his share dealing account to his ISA, a transaction known as a ’Bed & ISA’ transfer.
Following this transfer, Dr. Hudson’s total stake in the company amounts to 20,506,474 shares, which represents 5.51% of EDX Medical’s total voting rights. The company’s directors have taken responsibility for the contents of this announcement.
EDX Medical is known for creating advanced diagnostic products and services that aid in the personalized treatment of diseases such as cancer, cardiovascular issues, and infectious diseases. The company’s operations are based in Cambridge and Oxford, UK, with partnerships in place, including one with Thermo Fisher (NYSE:TMO) EMEA Ltd., to enhance its offerings in clinical diagnostics.
The company adheres to stringent industry standards, with product development, validation, and distribution processes conforming to ISO 13485, and its PCR and genomic sequencing services accredited to ISO 15189 by the United Kingdom (TADAWUL:4280) Accreditation Service (UKAS).
This announcement, containing inside information as defined under the UK version of the Market Abuse Regulation, signifies that this information is now publicly available.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.